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Abstract
Background: Curcumin is a spice and a coloring food compound with a promising role in colon
cancer prevention. Curcumin protects against development of colon tumors in rats treated with a
colon carcinogen, in colon cancer cells curcumin can inhibit cell proliferation and induce apoptosis,
it is an anti-oxidant and it can act as an anti-inflammatory agent. The aim of this study was to
elucidate mechanisms and effect of curcumin in colon cancer cells using gene expression profiling.
Methods: Gene expression changes in response to curcumin exposure were studied in two
human colon cancer cell lines, using cDNA microarrays with four thousand human genes. HT29
cells were exposed to two different concentrations of curcumin and gene expression changes were
followed in time (3, 6, 12, 24 and 48 hours). Gene expression changes after short-term exposure
(3 or 6 hours) to curcumin were also studied in a second cell type, Caco-2 cells.
Results: Gene expression changes (>1.5-fold) were found at all time points. HT29 cells were more
sensitive to curcumin than Caco-2 cells. Early response genes were involved in cell cycle, signal
transduction, DNA repair, gene transcription, cell adhesion and xenobiotic metabolism. In HT29
cells curcumin modulated a number of cell cycle genes of which several have a role in transition
through the G2/M phase. This corresponded to a cell cycle arrest in the G2/M phase as was
observed by flow cytometry. Functional groups with a similar expression profile included genes
involved in phase-II metabolism that were induced by curcumin after 12 and 24 hours. Expression
of some cytochrome P450 genes was downregulated by curcumin in HT29 and Caco-2 cells. In
addition, curcumin affected expression of metallothionein genes, tubulin genes, p53 and other
genes involved in colon carcinogenesis.
Conclusions: This study has extended knowledge on pathways or processes already reported to
be affected by curcumin (cell cycle arrest, phase-II genes). Moreover, potential new leads to genes
and pathways that could play a role in colon cancer prevention by curcumin were identified.
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Background
Curcumin (diferuloylmethane) is a spice and a coloring
agent derived from the root of the plant Curcuma longa to
which colon cancer-preventive properties have been
attributed. It is present in curry and mustard, and it is used
extensively in Asian countries, also in traditional medi-
cine. The low incidence of colon cancer in Asian countries
could be related to low meat intake, but also to the regular
use of curcumin in the diet [1].
In rats and mice curcumin has a profound effect on colon
carcinogenesis. In rats treated with colon carcinogen
azoxymethane (AOM), for example, consuming a diets
with 2000 ppm curcumin resulted in a significant reduc-
tion of the number of aberrant crypt foci (ACF) after 9
weeks [2] and after 52 weeks incidence and multiplicity of
colon adenocarcinomas were significantly reduced [3].
Similarly, incidence and multiplicity of adenomas was
decreased in AOM-treated rats fed a diet with 8 or 16 g/kg
curcumin for 45 weeks [4]. Also in a mouse model with a
mutation in the APC gene curcumin reduced the number
of colon tumors [5] or the multiplicity of colon adenomas
[6]. Moreover, curcumin was found to protect against
development of colon cancer during both the initiation
and the promotion stage in AOM-treated rats and AOM-
treated mice [7,8]. In addition to the effect on colon can-
cer, curcumin showed anticancer effects in intestinal can-
cer, stomach cancer and hepatocellular carcinoma [9-11].
In vitro, curcumin caused a dose-dependent decrease in
cell proliferation in colon cancer cells and the cells accu-
mulated in the G2/M phase [12-14]. Apoptosis was
increased in colon cancer cells in response to curcumin
[13,14]. Also in other cell lines, e.g. breast cancer cells,
prostate cancer cells and leukaemia cells, curcumin inhib-
ited cell proliferation and induced apoptosis [15-19]. In
addition to inhibition of cell proliferation and increased
apoptosis, many mechanisms have been proposed to
explain the anti-carcinogenic effect of curcumin, includ-
ing its anti-inflammatory and antioxidant activity, induc-
tion of phase-II detoxification enzymes, inhibition of
cyclooxygenase 2 (COX-2), effect on AP-1 and NFκB tran-
scription factors, inhibition of matrix metalloproteinase
(MMP), effect on protein kinases and more [20-22].
In rats absorption of curcumin from the intestine was
reported to be about 60% [23]. Curcumin and metabo-
lites formed in intestine and liver are mostly excreted in
the faeces [24,25]. As the colon is exposed to both curcu-
min and its metabolites, it is a likely target for the anticar-
cinogenic activity of these compounds. Moreover, the fact
that humans were able to consume up to 8 grams of cur-
cumin per day without toxic effects [26] makes curcumin
a very interesting chemopreventive agent.
New techniques, like multiple gene expression analysis
using microarrays, allow for a more comprehensive study
of the effects and mechanisms of food components. By
using cDNA microarrays the expression of thousands of
genes can be studied in one experiment. The power of
these techniques lies not only in the fact that many genes
can be studied in one experiment, but also in the possibil-
ity to identify leads to pathways and mechanisms, as
opposed to the extrapolation of assessments of a few
genes. In addition, multiple gene expressions can be
applied as 'fingerprint' biomarkers.
The aim of our study was to use new and genome-wide
information on the gene expression profile induced by
curcumin in colon cancer cells to elucidate mechanisms
involved in the cancer-preventive action of curcumin.
Therefore, HT29 colon cancer cells were exposed to two
concentrations of curcumin and gene expression changes
were measured at five exposure time points ranging from
3 hours to 48 hours. In addition, the response to short-
term exposure to curcumin (3 and 6 hours) was also stud-
ied in Caco-2 cells. Furthermore, in HT29 cells changes in
expression of cell cycle genes in response to curcumin
were related to changes in cell cycle distribution. The
time- and concentration-dependent changes in gene
expression in HT29 and Caco-2 cells are reported and
unique findings and observed similarities are discussed in
relation to data from other (microarray) studies to gain
more insight into mechanisms of cancer prevention by
curcumin.
Methods
Cell culture
HT29 cells (ATCC, Rockville, USA) were grown in
McCoy's 5 A medium with L-glutamine (Gibco BRL Life
Technologies) with 10% FCS. Caco-2 cells (ATCC, Rock-
ville, USA) were grown in DMEM with 25 mM HEPES,
without sodium pyruvate, with 4500 mg/l glucose, with
pyridoxine (Gibco BRL Life Technologies), to which was
added 10% FCS, 1% non-essential amino acids (Gibco
BRL Life Technologies) and 2% penicillin/streptomycin
(Gibco BRL Life Technologies). Cells were maintained at
37°C in a humidified atmosphere containing 5% CO2.
Curcumin (Sigma, St. Louis, MO, USA) was dissolved in
DMSO. At 70% confluence HT29 cells and Caco-2 cells
were exposed to 30 µmol/L (referred to as low concentra-
tion) or 100 µmol/L curcumin (referred to as high concen-
tration) for 3 or 6 hours. In addition, HT29 cells were
exposed to 25 µmol/L (referred to as low concentration)
or 100 µmol/L curcumin (referred to as high concentra-
tion) for 12, 24 or 48 hours. The final DMSO concentra-
tion in the medium was 0.1%.Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/8
Page 3 of 17
(page number not for citation purposes)
Cell cycle analysis using flow cytometry
HT29 cells were plated at a density of 3 × 105 cells in 25
cm2 culture flasks. After 24 hours, cells were exposed to
curcumin. After the exposure period cells were trypsinized
and collected in the original medium (to include floating
cells in the analysis). Cells were pelleted by centrifugation
at 500 × g at 4°C and washed with PBS. Cells were resus-
pended in PBS, ice-cold ethanol (75%) was added to the
cells while vortexing and cells were incubated on ice for 1
hour to fixate the cells. Cells were washed with PBS and
finally PBS with propidium iodide (Sigma, St. Louis, MO,
USA; 50 µg/ml) and Rnase A (Qiagen, Hilden, Germany;
0.1 mg/ml) was added. After incubation for 30 min in the
dark, cells were analysed using an Epics XL-MCL flow
cytometer (Beckman Coulter). P-values for difference
between cell cycle distribution in treated cells and in
untreated cells were calculated using a Student's t-test.
Also, after trypsinization cells were counted using a
Bürker-Turk counting chamber.
RNA isolation
After exposure total RNA was isolated from the cells using
Trizol (Life Technologies S.A., Merelbeke, Belgium)
according to the manufacturer's protocol. RNA clean-up
and Dnase digestion was performed using the RNeasy
mini kit (Qiagen, Hilden, Germany). RNA was checked
for purity and stability by gel electrophoresis and UV spec-
trometry. Absorption at 260 and 280 nm was measured
and RNA quantity and A260/A280 ratio were calculated.
Only RNA samples with A260/A280 ratio > 1.6 were used in
further experiments. Similar to other studies [27,28], RNA
from two or three exposure experiments was pooled
before labelling and hybridisation to reduce possible bias
from single exposure.
Quantitative real-time polymerase chain reaction
2 µg of total RNA was reverse transcribed into cDNA using
250 ng random hexamer primers and 200 units M-MLV
reverse transcriptase (Invitrogen Life Technologies, Breda,
the Netherlands) in a final volume of 20 µl. The same
batch of cDNA was used for all real-time PCR experi-
ments. Real-time PCR was performed using an iCycler
PCR machine (Biorad, Veenendaal, the Netherlands) and
the QuantiTect SYBR Green PCR kit (Qiagen, Hilden, Ger-
many). For all types of amplicon reactions were per-
formed in a final volume of 25 µl containing 400 nM of
each primer, 5 µl of diluted cDNA preparation (equivalent
to 50 or 5 ng of starting RNA) and 1× QuantiTect SYBR
Green Master Mix (Qiagen, Hilden, Germany). GAPDH
and beta actin expression was measured to correct for dif-
ferences in efficiency during reverse transcription. The
primer pairs used to amplify beta-actin, GAPDH, AKR1C1
and EGR1 were as follows: beta-actin upstream: 5'-CAC
CCC GTG CTG CTG AC-3', downstream: 5'-CCA GAG
GCG TAC AGG GAT AG-3'; GAPDH upstream: 5'-TGC
ACC ACC AAC TGC TTA GC-3', downstream: 5'-GGC ATG
GAC TGT GGT CAT GAG-3'; AKR1C1 upstream: 5'-CGT
GGG AGG CCG TGG AGA AG-3', downstream: 5'-GCT
GCC TGC GGT TGA AGT TGG-3'; EGR1 upstream: 5'-GTC
CCC GCT GCA GAT CTC T-3', downstream: 5'-CTC CAG
CTT AGG GTA GTT GTC CAT-3'.
Before real-time PCR analyses the specificity of the used
primer pairs and the correct size of the obtained PCR
products was checked by gel electrophoresis. At the end of
all real-time PCR runs, a melt curve peak analysis was per-
formed to ensure amplification of only the correct
product.
Amplification efficiency for each gene was calculated
using a dilution series from a mixture of all cDNAs, as rec-
ommended in Pfaffl et al. [29]. A threshold was chosen so
that for all samples in the dilution series amplification
was in the exponential phase and the correlation coeffi-
cient (as found for the linear relation between threshold
cycle value and logarithm of starting quantity) was maxi-
mal. This threshold level was also applied to determine
the threshold cycle value for all individual samples. Each
sample was measured in duplo at two different starting
concentrations of cDNA (equivalent to 50 or 5 ng of start-
ing RNA).
cDNA microarray preparation
A set of 4069 sequence-verified human cDNA clones from
the I.M.A.G.E. consortium was purchased (Research
Genetics, U.S.A.) as PCR products. The cDNA was ampli-
fied by PCR with forward (5'-CTGCAAGGCGATTAAGTT-
GGGTAAC-3') and reverse (5'-
GTGAGCGGATAACAATTTCACACAGGAAACAGC-3')
primers. The primers contained a 5'-C6-aminolinker (Iso-
gen Bioscience, Maarsen, The Netherlands) to facilitate
cross-linking to the aldehyde-coated glass microscope
slides. PCR products were checked by electrophoresis on a
1% agarose gel. PCR products were purified by isopropa-
nol precipitation and washing in 70% ethanol, and were
dissolved in 3 × SSC. The clones were spotted on CSS-100
silylated aldehyde glass slides (TeleChem, Sunnyvale, CA,
USA) in a controlled atmosphere. To reduce free aldehyde
residues, slides were blocked with borohydride after spot-
ting and drying. Slides were stored in the dark and dust-
free until further use.
Labelling and hybridisation
Total RNA (25 µg) was labelled using CyScribe first-strand
cDNA labelling kit (Amersham Biosciences, Freiburg, Ger-
many). During reverse transcription of the RNA, Cy3- or
Cy5-labelled dUTP was built into the cDNA. After incu-
bating the reaction for 1.5 h at 42°C, RNA was hydrolysed
by adding NaOH. After neutralisation, free nucleotidesJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/8
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were removed from the solution using AutoSeq G50 col-
umns (Amersham Biosciences, Freiburg, Germany).
Each sample was labelled twice, once with Cy3 and once
with Cy5. cDNA from cells exposed to curcumin (treated
sample) was hybridised to the microarray in competition
with cDNA from cells exposed to DMSO only (untreated
sample), while one of the samples was labelled with Cy3
and the other with Cy5. Hybridisations were repeated
with a dye swap.
Before hybridisation, Cy3- and Cy5-labeled cDNAs were
mixed and human cot-1 DNA (3 µg, Life Technologies
S.A., Merelbeke, Belgium), yeast tRNA (100 µg, Life Tech-
nologies S.A., Merelbeke, Belgium) and poly(dA-dT) (20
µg, Amersham Biosciences, Freiburg, Germany) were
added to avoid non-specific binding. The hybridisation
mix was dissolved in 30 µl Easyhyb hybridisation buffer
(Roche Diagnostics, Mannheim, Germany), denatured for
1.5 min at 100°C and incubated for 30 minutes at 42°C.
Before adding the hybridisation mix to the slides, slides
were prehybridised in prehybridisation buffer (5 × SSC,
0.1 % SDS and 10 mg/ml bovine serum albumin) for 45
minutes at 42°C, washed in milliQ water, washed with
isopropanol and dried.
After pipetting the hybridisation mix on the slides, the
slides were covered with a plastic coverslip and hybridised
overnight in a slide incubation chamber (Corning, Life
Sciences, Schiphol, the Netherlands) submerged in a
42°C waterbath. After hybridisation, slides were washed
by submersion and agitation in 0.5 × SSC with 0.2% SDS
and in 0.5 × SSC. Then, slides were firmly shaken in 0.2 ×
SSC and put on a rotation plateau for 10 min. This step
was repeated once and slides were dried quickly by centrif-
ugation at 700 rpm.
Slides were scanned with a ScanArray Express confocal
laser scanner (Perkin Elmer Life Sciences, USA) and
Imagene 4.0 (Biodiscovery Inc., Los Angeles, USA) was
used to extract data from the images, with automatic flag-
ging of weak or negative signals and spots with non-
homogeneous signal.
Data analysis
Data were imported into SAS Enterprise guide V2 (SAS
Institute Inc., Cary, USA). Spots with a signal/background
ratio less than 1.5 or spots that were flagged by the
Imagene software were not included in the data analysis.
For each spot, local background intensity was subtracted
from mean signal intensity and the expression ratio was
calculated by dividing background-corrected signal inten-
sity of the treated sample by the background-corrected sig-
nal intensity of the untreated sample. Expression ratios
were then log transformed (base 2), normalised per slide
using an intensity-dependent method (Lowess) [30] and
scaled. Data were transferred to Microsoft Excel 97
(Microsoft Corporation, USA). Expression ratios of duplo
(dye swap) arrays were combined and an average expres-
sion ratio was calculated, provided that an expression
ratio was present for both arrays. In addition, genes that
showed specific dye bias at all timepoint were excluded
from further analysis and when looking for early or late
response genes only genes that did not show dye bias were
included.
Since it is impossible to report results for all genes on the
array for all time points, we chose to look at genes with a
relatively large change in expression over time. Among
these genes we identified early response genes (which
were more than 1.5 fold induced or repressed after 3 or 6
hours of exposure) and genes that respond at later time
points. In addition, we identified genes with similar
responses to curcumin within a pathway and we looked at
pathways known to be important in colon carcinogenesis,
like cell cycle control and apoptosis. Clustering methods
like K-means clustering http://ep.ebi.ac.uk/EP/EPCLUST/
were used to identify genes with a similar expression pro-
file over the different time points.
Principal Component Analysis
To analyze and visualize the results of the microarray
experiments Principal Component Analysis (PCA) was
used, which is a well-known pattern recognition method
in the field of multivariate data analysis. Data analysis was
performed using the Matlab software (The MathWorks,
Inc., 1984–2001) version 6.1.0.450 (R12.1). For PCA
analysis the procedure from the PLS Toolbox was used
(Version 2.0.1b 1999, Eigenvector Research, Inc., 1995–
1999). Average expression ratios were used in the PCA
analysis. Only genes with less than three missing values
among the different time points were included. Before
PCA analysis, data sets were mean-centered.
Results
Curcumin exposure resulted in gene expression changes
in HT29 cells at all time points. However, after exposure
to curcumin for 48 hours only 20–30 genes were up- or
downregulated more than 1.5 fold, while after for exam-
ple 3 or 12 hours about 130 genes were up- or downregu-
lated more than 1.5 fold. The total set of gene expression
data was submitted to principal component analysis
(PCA), identifying the two major components within the
total variation between samples, which are then visual-
ized in a two-dimensional plot in which the expression
profiles at each of the time points are projected. This PCA
plot (Figure 1) nicely visualizes the time-dependent
changes in the gene expression patterns. Interestingly, the
time-dependent shift of the overall gene expressionJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/8
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patterns is similar for the low and the high curcumin con-
centration. The points representing the gene expression
patterns after exposure to curcumin for 48 hours are plot-
ted quite distantly from the gene expression patterns at
the other time points, also indicating that the expression
patterns of the cells exposed to curcumin for 48 hours are
different from the gene expression patterns at the other
time points.
Early response genes were defined as genes that were dif-
ferentially expressed after exposure to curcumin for 3 or 6
hours. A selection of the early response genes in HT29
cells is listed in table 1 (low concentration) and table 2
(high concentration). Early response genes were involved
in several processes, including cell cycle control, signal
transduction, DNA repair, transcription regulation, cell
adhesion and xenobiotic metabolism. Both curcumin
concentrations caused an increase in expression of genes
involved in DNA repair, e.g. MLH1, MSH3 and ERCC2
(Tables 1 and 2). Upregulated signal transduction genes
included STAT3 and STAT5b (Table 1) and some genes of
the MAPK signal transduction pathway (MAP3K10,
MAP4K2; table 1 and 2). Some other MAPK signal trans-
duction genes were downregulated by the low curcumin
concentration (Table 1). Expression of a group of genes
involved in cell adhesion and protein binding was
induced by short-term exposure to curcumin, including
annexin (Table 1) and integrin genes (Table 2). Several
genes involved in xenobiotic metabolism were downregu-
lated after short-term exposure to the high concentration
of curcumin, namely GSTT2, GSTM4, CYP1B1 (Table 2).
Expression of GCLC, involved in glutathione synthesis,
was upregulated after 6 hours (Table 2).
Also, genes involved in transcription regulation were
induced or repressed by short-term exposure to curcumin.
Principal Component Analysis (PCA) Figure 1
Principal Component Analysis (PCA). The gene expression pattern at each time point is visualized as a dot in this two-dimen-
sional graph. The axes show the scores of the gene expression profiles of HT29 cells at the specific time points after exposure 
to curcumin in principal component (PC) 1 and 2 (which explain the largest part of the variance). The variance explained by the 
PCs is indicated between parentheses. Open circles and dotted arrows indicate exposure to the low curcumin concentration, 
filled circles and solid arrows indicate exposure to the high curcumin concentration.
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Among these were transcription factors such as activating
transcription factor 4 (ATF4) and early growth response 1
(EGR1) (Table 2). One of the target genes regulated by
ATF4 is asparagine synthetase (ASNS) [31]. Figure 2 shows
the expression profile of ATF4 and ASNS in response to
curcumin. Induction of ATF4 expression at the early time
points is followed by induction of expression of ASNS at
the same and later time points. EGR1, a transcription fac-
tor involved in cell growth regulation and tumor suppres-
sion [32], was the most upregulated early response gene.
In contrast to this strong upregulation after exposure to
the high concentration of curcumin, this gene was not
Table 1: Early response genes in HT29 cells after exposure to low concentration of curcumin (30 µmol/L).
Fold change 
(treated/control)
Accession number Gene Name Gene Symbol 3 h 6 h Involved in
R10662 mutL homolog 1, colon cancer, nonpolyposis type 2 
(E. coli)
MLH1 1.90 1.04 DNA repair
AA421716 mutS homolog 3 (E. coli) MSH3 1.11 1.53 DNA repair
R54492 excision repair cross-complementing rodent repair 
deficiency, complementation group 2
ERCC2 1.63 1.20 DNA repair
AA399410 signal transducer and activator of transcription 3 
(acute-phase response factor)
STAT3 1.56 1.19 Signal transduction/transcription 
regulation
AA280647 signal transducer and activator of transcription 5B STAT5B 1.67 -1.04 Signal transduction/transcription 
regulation
AA434420 protein tyrosine phosphatase, non-receptor type 9 PTPN9 1.74 1.64 Signal transduction
H01340 mitogen-activated protein kinase kinase kinase 10 MAP3K10 1.83 1.42 Signal transduction
AA425826 mitogen-activated protein kinase kinase 2 MAP2K2 -1.72 -1.03 Signal transduction
T94169 mitogen-activated protein kinase 8 MAPK8 -1.55 1.16 Signal transduction
R82176 MAD, mothers against decapentaplegic homolog 7 MADH7 -1.77 NA1 Signal transduction
N71159 metastasis associated 1 MTA1 1.68 NA Transcription regulation
AA448256 metal-regulatory transcription factor 1 MTF1 -1.34 -1.66 Transcription regulation
AA465236 forkhead box O3A FOXO3A -1.43 -2.01 Transcription regulation
AA775415 SMT3 suppressor of mif two 3 homolog 2 (yeast) SMT3H2 -1.77 -1.57 Nuclear transport
T54121 cyclin E1 CCNE1 1.63 NA Cell cycle
N74285 CDC5 cell division cycle 5-like CDC5L 1.51 1.05 Cell cycle
AA789328 cyclin-dependent kinase (CDC2-like) 10 CDK10 1.51 NA Cell cycle
AA877595 cyclin-dependent kinase inhibitor 2A (melanoma, p16, 
inhibits CDK4)
CDKN2A 1.49 1.86 Cell cycle
AA488324 BUB1 budding uninhibited by benzimidazoles 1 
homolog beta (yeast)
BUB1B -1.95 NA Cell cycle
R19158 serine/threonine kinase 6 STK6 -1.25 -1.80 Cell cycle
AA071486 serine/threonine kinase 12 STK12 -1.50 -1.83 Cell cycle
AA082943 cyclin G1 CCNG1 -1.54 1.24 Cell cycle
W51794 matrix metalloproteinase 3 (stromelysin 1, 
progelatinase)
MMP3 -1.12 1.52 Breakdown of extracellular 
matrix
N33214 matrix metalloproteinase 14 (membrane-inserted) MMP14 -1.53 NA Breakdown of extracellular 
matrix
AA406571 carcinoembryonic antigen-related cell adhesion 
molecule 1 (biliary glycoprotein)
CEACAM1 1.76 1.18 Cell adhesion
AA464982 annexin A11 ANXA11 1.75 1.13 Protein binding
AA419015 annexin A4 ANXA4 NA 1.79 Protein binding
AA856874 furin (paired basic amino acid cleaving enzyme) FURIN 1.87 1.48 Proprotein convertase
R26186 protein phosphatase 1, catalytic subunit, beta isoform PPP1CB 1.64 1.65 Phosphatase activity
N28497 protein phosphatase 2 (formerly 2A), regulatory 
subunit A (PR 65), beta isoform
PPP2R1B 1.91 NA Phosphatase activity
AA877845 LIM domain kinase 2 LIMK2 1.88 1.56 Protein-protein interactions
AA634028 major histocompatibility complex, class II, DP alpha 1 HLA-DPA1 -2.06 NA Immune-related
T63324 major histocompatibility complex, class II, DQ alpha 1 HLA-DQA1 1.60 1.17 Immune-related
H95960 secreted protein, acidic, cysteine-rich (osteonectin) SPARC -1.13 -1.79 Collagen-binding Calcium-binding
AA456291 Developmentally regulated GTP binding protein 2 DRG2 1.67 1.47 GTP-binding protein
AA430178 RAN binding protein 2-like 1 RANBP2L1 -1.85 -1.11 GTP-binding protein
1 NA: not availableJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/8
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induced by the low curcumin concentration (Figure 3A).
Expression of EGR1 was also measured by real-time RT-
PCR. The induction factor for EGR1 after 3 hours of expo-
sure to the high curcumin concentration was even higher
when measured with real-time PCR than with the cDNA
microarray (23.0 ± 2.73 when normalised to beta-actin
and 30.5 ± 2.96 when normalised to GAPDH versus 8.7 as
measured on cDNA microarray). Similarly,
downregulation of EGR1 after 12 hours (2-fold) and
upregulation after 24 hours of exposure (1.4-fold) were
confirmed by real-time RT-PCR analysis of the effects on
EGR1 expression (data not shown).
In addition to the functional groups mentioned above
several genes involved in the cell cycle or cell growth were
among the early response genes. For example several
growth factors (AREG, VEGF, FGFR1) were upregulated
three hours after exposure to the high concentration of
curcumin (Table 2). At the same time point, expression of
cyclin-dependent kinase inhibitor p16INK4 (CDKN2A)
Table 2: Early response genes in HT29 cells after exposure to high concentration of curcumin (100 µmol/L).
Fold change 
(treated/control)
Accession number Gene Name Gene Symbol 3 h 6 h Involved in
AA421716 mutS homolog 3 (E. coli) MSH3 1.52 1.47 DNA repair
R91570 signal transducer and activator of transcription 4 STAT4 1.17 -1.57 Signal transduction
H01340 mitogen-activated protein kinase kinase kinase 10 MAP3K10 1.81 1.33 Signal transduction
R50953 mitogen-activated protein kinase kinase kinase kinase 
2
MAP4K2 1.65 NA1 Signal transduction
R38343 protein tyrosine phosphatase, receptor type, G PTPRG 1.56 1.05 Signal transduction
AA486533 early growth response 1 EGR1 8.66 1.29 Transcription regulation
AA600217 activating transcription factor 4 (tax-responsive 
enhancer element B67)
ATF4 1.94 NA Transcription regulation
R83270 TGFB-induced factor (TALE family homeobox) TGIF -1.97 -1.06 Transcription regulation
AA733038 polymerase (RNA) I polypeptide C, 30 kDa POLR1C -1.66 -1.09 Transcription regulation
AA857163 amphiregulin (schwannoma-derived growth factor) AREG 1.98 1.23 Growth factor (cell cycle)
R45059 vascular endothelial growth factor VEGF 1.78 NA Growth factor (cell cycle)
R54846 fibroblast growth factor receptor 1 FGFR1 1.78 NA Cell growth (signal transduction)
AA877595 cyclin-dependent kinase inhibitor 2A (melanoma, p16, 
inhibits CDK4)
CDKN2A 1.72 NA Cell cycle
AA450265 proliferating cell nuclear antigen PCNA -1.59 -1.09 Cell cycle
N74956 insulin-like growth factor binding protein 7 IGFBP7 -1.55 -1.39 Cell proliferation
AA180742 tubulin, alpha 1 (testis specific) TUBA1 -1.53 -1.09 Cytoskeleton
AA480995 methylene tetrahydrofolate dehydrogenase (NAD+ 
dependent), methenyltetrahydrofolate cyclohydrolase
MTHFD2 1.79 1.56 Single carbon unit transfer
H23187 carbonic anhydrase II CA2 -1.09 -1.69 Single carbon unit transfer
AA037229 integrin, beta 3 (platelet glycoprotein IIIa, antigen 
CD61)
ITGB3 -1.21 -1.50 Cell adhesion
AA485668 Integrin, beta 4 ITGB4 1.82 1.21 Cell adhesion
W56754 Integrin, beta 8 ITGB8 1.51 -1.08 Cell adhesion
R48796 integrin, alpha L (antigen CD11A (p180), lymphocyte 
function-associated antigen
ITGAL 1.50 1.19 Cell adhesion
AA159577 mucin 5, subtype B, tracheobronchial MUC5B 1.84 1.27 Extracellular matrix formation
AA490208 glutathione S-transferase theta 2 GSTT2 -1.56 -1.48 Xenobiotic metabolism
AA486570 glutathione S-transferase M4 GSTM4 -1.13 -1.54 Xenobiotic metabolism
AA448157 cytochrome P450, family 1, subfamily B, polypeptide 1 CYP1B1 -1.74 -1.33 Xenobiotic metabolism
H56069 glutamate-cysteine ligase, catalytic subunit GCLC -1.16 1.52 Glutathione synthesis
AA759046 dual specificity phosphatase 2 DUSP2 2.31 1.24 Inactivation MAPK family kinases
AA187349 ferredoxin 1 FDX1 -1.57 NA Electron transfer, metabolism
AA450205 translocation protein 1 TLOC1 -1.54 -1.54 Protein transport
H13691 major histocompatibility complex, class II, DM beta HLA-DMB 1.51 -1.01 Immune-related
T70057 immunoglobulin J polypeptide IGJ -1.91 1.02 Immune-related
AA496359 immediate early protein ETR101 1.54 1.10 Unknown
AA425687 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1 DDX1 -1.56 NA Unknown
1 NA: not availableJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/8
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was upregulated (Table 2). Expression of cell growth
related genes PCNA and IGFBP7 was downregulated by
the high concentration of curcumin (Table 2). Also after
exposure to the low curcumin concentration some cell
cycle genes were downregulated, like BUB1B (a mitotic
checkpoint gene), STK6, STK12 and cyclin G1 (CCNG1).
Upregulated cell cycle genes included CDK10, CDC5L
and cyclin E1 (CCNE1), but also cell cycle inhibitor
p16INK4 (CDKN2A) (Table 1). Also at later time points
differential expression of genes involved in cell cycle or
cell growth was found. One of the most strongly downreg-
ulated genes in HT29 cells was polo-like kinase (PLK),
after exposure to the high curcumin concentration for 24
hours (fig. 3B). PLK is a cell cycle gene involved in spindle
assembly. It is expressed at a higher level in colorectal can-
cer than in normal colon tissue [33]. Downregulation of
PLK has been shown to inhibit cell growth in cancer cells
[34]. Several histone genes (H3F3A, HIST1H4C) were
downregulated by curcumin, especially at the 12 h and 24
h time points (data not shown). Histone deacetylase
(HDAC1) was downregulated 1.7-fold by the high con-
centration of curcumin after 24 hours. Other genes
involved in cell cycle control that were differentially
expressed after 12 or 24 hour exposure to high concentra-
tion curcumin were retinoblastoma 1 (RB1), MAD2L1,
BUB1, cyclin G1 (downregulated 1.6 to 2-fold). In
response to exposure to the low concentration of curcu-
min for 12 hours expression of cyclin H was downregu-
lated (1.5-fold) and expression of cyclin A2 was
upregulated (1.7-fold). In contrast to cell cycle-related
genes, only a few genes involved in apoptosis were differ-
entially expressed in response to curcumin. The most
striking effect was observed with programmed cell death 2
(PDCD2), which was downregulated 1.8-fold by the high
concentration of curcumin after exposure for 12 hours.
When looking in detail into the gene expression profiles
at the different time-points, several genes known to be
involved in colon carcinogenesis were found that
responded to curcumin exposure. Expression changes of
these genes are shown in figure 3. Protein expression of
urokinase-type plasminogen activator (PLAU) was
reported to be higher in colon tumours than in normal
colon tissue [35]. In our study, curcumin downregulated
expression of PLAU in HT29 cells (Figure 3). In addition,
expression of urokinase-type plasminogen activator recep-
tor (PLAUR) was upregulated by curcumin (Figure 3).
Recently, it was shown that members of the transmem-
brane 4 superfamily could play a role in colon cancer [36].
Two members of this family, TM4SF1 and TM4SF4,
showed differential responses to exposure to curcumin
(Figure 3 and 3). Expression of carbonic anhydrase 2
(CA2) was found to be downregulated in colon tumors
[37,38]. In this study, expression of CA2 was downregu-
lated in response to exposure to curcumin (Figure 3).
Expression of protein kinase B (AKT1) was upregulated by
the low curcumin concentration after 3 hours and by the
high curcumin concentration after 24 hours (Figure 3)
Protein kinase B/Akt is an important part of signal trans-
duction pathways regulating for example apoptosis. Cur-
cumin downregulated expression of tumor protein p53
(TP53) (Figure 3), a transcription factor that has a role in
cell cycle control [39]. Expression of methylene tetrahy-
drofolate dehydrogenase/cyclohydrolase (MTHFD2) was
upregulated at early time points and downregulated at the
later time points. This gene has a role in the maintenance
of the single carbon metabolic pool carried by folate.
Folate could be involved in colorectal carcinogenesis
through DNA methylation and polymorphisms in genes
involved in folate metabolism [40].
Clustering methods were used to identify groups of genes
with similar expression profile across the different time
points. Several functional groups of genes with a similar
Expression profile of activating transcription factor 4 (ATF4,  black bars) and asparagine synthetase (ASNS, grey bars) in  response to exposure to curcumin Figure 2
Expression profile of activating transcription factor 4 (ATF4, 
black bars) and asparagine synthetase (ASNS, grey bars) in 
response to exposure to curcumin. A: low concentration, B: 
high concentration.
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Expression profile of genes in response to curcumin; grey bars indicated the low concentration and black bars indicate the high  concentration Figure 3
Expression profile of genes in response to curcumin; grey bars indicated the low concentration and black bars indicate the high 
concentration. EGR1: early growth response 1; PLK: polo-like kinase; TP53: tumor protein p53; CA2: carbonic anhydrase 2; 
MTHFD2: methylene tetrahydrofolate dehydrogenase/cyclohydrolase; AKT1: protein kinase B/Akt; PLAU: urokinase-type plas-
minogen activator; PLAUR: urokinase-type plasminogen activator receptor; TM4SF1: transmembrane 4 superfamily member 1; 
TM4SF4: transmembrane 4 superfamily member 4.
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expression profile were found. Figure 4 shows the
response of the cluster of genes involved in phase-II
metabolism (biotransformation of electrophilic muta-
gens and other toxic compounds) to exposure to curcu-
min at the different time points. Curcumin induced
expression of these genes, with a maximum induction
after exposure for 12 or 24 hours. After 48 hours no differ-
ential expression is seen. The most upregulated gene is
aldo-keto reductase family 1 member C1 (AKR1C1). The
expression changes of AKR1C1 in response to curcumin
were confirmed with real-time RT-PCR (Figure 5). This
gene, also known as dihydrodiol dehydrogenase, was
recently shown to be underexpressed in 50% of gastric
cancers [41]. Previously it was also shown that gene
expression of AKR1C1 could be upregulated in HT29 cells
by phenolic antioxidants [42]. Isothiocyanates induced
protein expression of AKR1C1, NAD(P)H:quinone oxi-
doreductase 1 (NQO1) and heavy subunit of glutamate-
cysteine ligase (GCLC) in a colon cancer cell line [43].
These genes were also upregulated by curcumin in this
study. In addition, NQO2 and epoxide hydrolase 1
(EPHX1) were also upregulated (Figure 4). Several other
redox-sensitive genes were upregulated after short-term
exposure to the high concentration of curcumin, like
AREG, ATF4, EGR1, FGFR1 (Table 2) [44]. However, not
all phase-II genes were upregulated by curcumin. In this
study several GSTs were downregulated, e.g. GSTT2 and
GSTM4 (table 2), GSTZ1 (after exposure for 24 hours). In
addition, GCLM (the light regulatory subunit of gamma-
glutamylcysteine synthetase) was downregulated by cur-
cumin with maximal downregulation by the low concen-
tration of curcumin after 12 hours (1.8-fold) and by the
high concentration of curcumin after 24 hours (1.9-fold).
Response of genes involved in phase II metabolism to expo- sure to curcumin; A: low concentration, B: high  concentration Figure 4
Response of genes involved in phase II metabolism to expo-
sure to curcumin; A: low concentration, B: high concentra-
tion. AKR1C1: aldo-keto reductase family 1 member C1; 
NQO1: NAD(P)H dehydrogenase, quinone 1; NQO2: 
NAD(P)H dehydrogenase, quinone 2; TXNRD1: thioredoxin 
reductase 1; EPHX1: epoxide hydrolase 1.
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AKR1C1 gene expression changes in response to curcumin  [A: low concentration, B: high concentration], measured with  cDNA microarray (black bars), and measured by real time  RT-PCR normalized to beta-actin expression (white bars) or  to GAPDH expression (grey bars) Figure 5
AKR1C1 gene expression changes in response to curcumin 
[A: low concentration, B: high concentration], measured with 
cDNA microarray (black bars), and measured by real time 
RT-PCR normalized to beta-actin expression (white bars) or 
to GAPDH expression (grey bars). Expression is plotted as 
induction factors (level in treated cells compared to 
untreated cells) (mean ± standard deviation).
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Gamma-glutamyl hydrolase (GGH) was downregulated
1.5-fold by the high curcumin concentration after 24
hours. Several phase-I metabolism genes were downregu-
lated by curcumin, for example expression of CYP1B1 was
inhibited by the high curcumin concentration after 3
hours (Table 2) and expression of some other cytochrome
P450 genes was downregulated after exposure for 12
hours to the high curcumin concentration (data not
shown). Expression of the aryl hydrocarbon receptor
(AHR) was also slightly downregulated at this point (1.4-
fold).
A second group of genes that showed a similar response to
curcumin exposure in this study were metallothionein
genes. All were downregulated by curcumin, specifically at
the 12 and 24 hour time points (Figure 6). In addition, the
metallothionein downregulation was preceded by a
downregulation of MTF1, the transcription factor regulat-
ing metallothionein expression, by the low curcumin con-
centration (Table 1). In human colon cancer cells
metallothionein was found to be a possible proliferation
marker, as it is higher expressed in proliferating cells and
its expression is cell cycle regulated [45]. Expression of
metallothionein in colon tumors is associated with poor
prognosis [46].
Another group of genes that responded to curcumin expo-
sure in a similar fashion were tubulin genes. These genes
were downregulated after 3 hours, but were upregulated
after 48 hours of exposure to the high curcumin concen-
tration (Figure 7). Alpha tubulin has been reported to be
differentially expressed in normal colon compared to
colon tumors [47] and alpha tubulin was downregulated
during differentiation of HT29-D4 cells [48].
Several proteasome genes were upregulated by the high
concentration of curcumin after 12 or 24 hours: PSMA1,
PSMA7, PSMB2 after 12 hours and PSMB6, PSMC4,
PSMD2 after 24 hours (data not shown).
In addition to HT29 cells, expression changes at early time
points of exposure to curcumin were also studied in Caco-
2 cells. Fewer genes were differentially expressed in these
cells than in HT29 cells, between 20 and 50 genes were
up- or downregulated more than 1.5 fold after short-term
exposure to curcumin. The most striking response in
Caco-2 cells was a strong downregulation of CYP1A1
expression after exposure to both concentrations of curcu-
min for 3 and 6 hours (Table 3). CYP1A1 expression did
not change in HT29 cells in response to curcumin,
however CYP1B1 expression was downregulated by the
high concentration of curcumin (Table 2). Some genes
showed a similar response in Caco-2 cells as in HT29 cells,
for example EGR1 and AKR1C1. However, upregulation
Response of metallothionein (MT) genes 1B-1L to exposure  to curcumin; A: low concentration, B: high concentration Figure 6
Response of metallothionein (MT) genes 1B-1L to exposure 
to curcumin; A: low concentration, B: high concentration.
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B Response of tubulin genes in HT29 cells to exposure to cur- cumin (high concentration); TUBA1: tubulin, alpha 1; TUBA3:  tubulin, alpha 3; TUBB2: tubulin, beta 2 Figure 7
Response of tubulin genes in HT29 cells to exposure to cur-
cumin (high concentration); TUBA1: tubulin, alpha 1; TUBA3: 
tubulin, alpha 3; TUBB2: tubulin, beta 2.
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in Caco-2 cells (Table 3) was not as strong as in HT29 cells
(Figure 4 and 3). Expression of TLOC1 and POLR1C was
downregulated in Caco-2 cells (Table 3) as well as in
HT29 cells after short-term exposure (Table 1 and 2). Also
upregulation of ETR101 and an integrin gene in Caco-2
cells is consistent with the results in HT29 cells. In Caco-2
cells several transcription factors were upregulated by cur-
cumin, like NR2F1, NR4A1 and MTF1, whereas
transcription factor FOSB and transcription-related genes
HNRPA0 and POLR1C were downregulated (Table 3).
When HT29 cells were exposed to the low curcumin con-
centration for 6 hours, the number of cells was decreased
compared to cells not exposed to curcumin (Figure 8).
However, after 24 hours a difference with cells that were
not exposed to curcumin was no longer seen.
Exposure of the cells to the high concentration of curcu-
min caused a decrease in cell number at all time points
(Figure 8). After exposure to curcumin for 3 or 6 hours a
significant decrease in the percentage of cells in the G1
phase of the cell cycle and a significant increase in the
percentage of cells in the G2/M phase of the cell cycle was
observed (Figure 9). This effect was dose-dependent. At
the 24 hour time point the percentage of cells in the G1
phase was decreased significantly and the percentages of
cells in both the S and the G2/M phase were increased sig-
nificantly (Figure 9). When absolute cell numbers were
recalculated from the percentages, the number of cells in
G1 and S phase decreased significantly after exposure for
3 hours (only for the high curcumin concentration) or 6
hours. The absolute number of cells in G2/M phase
remained constant. After exposure to the low
Table 3: Early response genes in Caco-2 cells after exposure to curcumin.
Fold change 
(treated/control)
30 µmol/L 100 µmol/L
Accession number Gene Name Gene Symbol 3 h 6 h 3 h 6 h Involved in
AA418907 cytochrome P450, family 1, subfamily A, polypeptide 1 CYP1A1 -2.93 -3.00 -2.89 -6.39 Xenobiotic metabolism
R93124 aldo-keto reductase family 1, member C1 (dihydrodiol 
dehydrogenase 1)
AKR1C1 1.05 1.60 -1.15 1.18 Xenobiotic metabolism
AA486533 early growth response 1 EGR1 1.11 1.03 2.49 2.30 Gene transcription
AA452909 nuclear receptor subfamily 2, group F, member 1 NR2F1 -1.40 NA1 -1.20 1.83 Gene transcription
N94487 nuclear receptor subfamily 4, group A, member 1 NR4A1 -1.19 1.09 1.45 1.08 Gene transcription
AA448256 metal-regulatory transcription factor 1 MTF1 0.28 0.34 0.09 0.74 Gene transcription
T61948 FBJ murine osteosarcoma viral oncogene homolog B FOSB -1.37 1.21 -1.22 -1.62 Gene transcription
AA599176 heterogeneous nuclear ribonucleoprotein A0 HNRPA0 -1.05 -1.31 -1.12 -1.58 Gene transcription
AA733038 polymerase (RNA) I polypeptide C, 30 kDa POLR1C -1.22 -1.28 -1.34 -1.73 Gene transcription
AA464970 phospholipase C, beta 2 PLCB2 NA 1.93 1.08 1.05 Signal transduction
AA450205 translocation protein 1 TLOC1 1.15 -1.36 -1.20 -1.62 Protein transport
AA419177 solute carrier family 7, member 5 SLC7A5 -1.27 -1.54 -1.56 -1.99 Transport
AA425451 integrin, alpha E ITGAE NA 1.43 1.54 NA Cell adhesion
AA888148 tubulin, beta 2 TUBB2 -1.25 -1.25 -1.57 -1.97 Cytoskeleton
AA496359 immediate early protein ETR101 -1.09 -1.02 1.77 1.52 unknown
1 NA: not available
Number of HT29 cells after exposure to curcumin at differ- ent time points Figure 8
Number of HT29 cells after exposure to curcumin at differ-
ent time points. Black bars: untreated cells, grey bars: low 
concentration, white bars: high concentration. Values are 
mean ± standard deviation.
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concentration of curcumin for 24 hours, the absolute
number of cells in G1 phase decreased significantly, but
the absolute number of cells in S and G2/M phase
increased significantly (data not shown).
Discussion
In this study the effect of curcumin on gene expression in
HT29 colon cancer cells is determined at different time
points. In addition, gene expression changes in response
to short term exposure to curcumin were also studied in
Caco-2 cells. The concentrations of curcumin (in the
micromolar range) used in this study reflect the in vivo sit-
uation. Based on almost complete faecal excretion of cur-
cumin and its metabolites [24,25] and assuming a volume
of one liter in the stomach and a 10-fold dilution from
stomach to colon, the concentration of curcumin in the
intestinal lumen can be as high as 270 µmol/L after con-
suming one gram of curcumin, with a meal and/or as sup-
plements. A similar concentration range for curcumin in
colon was reported by Wortelboer et al. [49]. The highest
concentration used in this study was 100 µmol/L. Expo-
sure of HT29 cells to this curcumin concentration resulted
in a decrease in cell number and floating cells were seen
in the culture flasks after 24 or 48 hours. Therefore, it is
possible that gene expression changes after exposure to
100  µmol/L curcumin for longer time periods (24, 48
hours) were related to toxic effects of the compound.
The study set-up with a time series of exposure to curcu-
min allowed us to identify early response genes and gene
expression changes over time. Early response genes were
identified; these were involved in DNA repair, signal
transduction, transcription regulation, cell adhesion,
xenobiotic metabolism. Also, genes involved in cell cycle
control were up- or downregulated by short-term expo-
sure to curcumin. Additionally, we have shown that expo-
sure of HT29 cells to curcumin for 3 or 6 hours results in
a decrease in percentage of cells in G1 phase and an
increase in percentage of cells in G2/M phase. Other stud-
ies also reported a cell cycle arrest in the G2/M phase in
colon cancer cells after curcumin exposure (similar
concentrations, in micromolar range), but only exposure
periods of 12 hours or longer were studied [12-14]. In
addition, after 24 hours an increase in the percentage of
cells in the S phase was observed. Hanif et al. [12] also
found an increase in the percentage of cells in the S-phase
in HT29 cells after exposure to curcumin for 24 hours.
Interestingly, the initial decrease in cell number after
short-term exposure to the low concentration of curcumin
was no longer seen after 24 hours. At this time point,
exposure to the low curcumin concentration had resulted
in a significant increase in the absolute number of cells in
the S and G2/M phase when compared to cells that were
not exposed to curcumin. This indicates that the cells may
have overcome the cell growth-inhibiting effect of curcu-
min at this time point. Consistent with this cell-physio-
logical observation, changes in expression of cell cycle
genes were not found after exposure to the low curcumin
concentration for 24 hours.
The downregulation of expression of PLK by curcumin as
found in this study could be involved in the G2/M arrest.
Recently it was shown that downregulation of PLK in
colon cancer cell line SW480 resulted in an increase in the
percentage of cells in the G2/M phase [50]. Also in HeLa
cells, depletion of PLK resulted in G2/M phase arrest and
apoptosis [51]. Also other genes involved in transition
Cell cycle distribution of HT29 cells exposed to curcumin for  3, 6 or 24 hours, measured with propidium iodide assay Figure 9
Cell cycle distribution of HT29 cells exposed to curcumin for 
3, 6 or 24 hours, measured with propidium iodide assay. 
Black bars: untreated cells, grey bars: low concentration, 
white bars: high concentration. Values are mean ± standard 
deviation (n = 3 or 4). *: significantly different from untreated 
cells, P < 0.05
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through the G2/M phase of the cell cycle were
downregulated by curcumin, like BUB1B and MAD2L1.
Downregulation of HDAC1 by curcumin could possibly
also be related to the S/G2/M phase arrest, since exposure
of leukaemia cells to histone deacetylase inhibitors
resulted in a G2/M phase arrest [52]. In cancer cells
inhibition of histone deacetylase activity can cause growth
arrest and apoptosis, and thus inhibit carcinogenesis [53].
Recently, it was reported that HDAC1 is associated with
PCNA [54]. PCNA, involved in DNA replication, was also
downregulated by curcumin.
It is known that dietary curcumin can induce activity of
antioxidant or phase-II enzymes in livers of rats treated
with 1,2-dimethylhydrazine (DMH) or in liver and kidney
of ddY mice [55,56]. In this study, it was found that
curcumin also has an effect on phase-II enzyme gene
expression level in colonic cells. Induction of phase-II
genes can be a mechanism to protect against development
of cancer [57]. Expression of most of these genes is
induced through the antioxidant response element (also
known as EpRE) [58,59]. In human bronchial epithelial
cells curcumin increased EpRE-binding activity and
changed the composition of the EpRE-binding complex
[60]. One of the transcription factors present in the EpRE-
binding complex is Nrf2. Curcumin exposure resulted in
an increase in nuclear Nrf2 content in bronchial epithelial
cells [60] and in increased expression of Nrf2 in renal epi-
thelial cells [61]. Unfortunately, Nrf2 was not represented
on the cDNA microarray used in this study. Possibly, tran-
scription factor ATF4 can form a dimer with Nrf2 [62],
suggesting a role in EpRE-mediated effects. Indeed, curcu-
min was found to upregulate expression of ATF4 at the
early time points, consistent with its role as an initiator of
the curcumin effect through gene transcription modula-
tion. Curcumin downregulated expression of several GST
genes. This corresponds to an earlier observation that
GSTP1 expression was downregulated by curcumin in leu-
kaemia cells [63]. Overall, the effect of curcumin on the
phase-II and redox-sensitive genes could indicate an
increased level of protection of the cells against oxidative
stress, consistent with its function as an anti-oxidant. In
addition to its effect on phase-II biotransformation genes,
it is suggested that curcumin can inhibit activation of
carcinogens by cytochrome P450 enzymes [64]. In Caco-
2 cells curcumin caused a strong downregulation of
CYP1A1 gene expression. In HT29 cells curcumin down-
regulated expression of the CYP1B1 and aryl hydrocarbon
receptor genes.
Changes in expression of cell cycle-related genes together
with induced cell cycle arrest as well as induction of
phase-II genes can be mechanisms of colon cancer preven-
tion. Differential expression of tubulin genes and of pro-
teasome genes in response to curcumin could also be
interesting in view of the anticarcinogenic effect of curcu-
min. Microtubules formed by tubulin are important for
spindle formation during cell division [65]. Protein
degradation by proteasomes plays a role in cell cycle con-
trol and apoptosis and proteasome inhibitors are tested
for use in anticancer therapy [66]. Furthermore, downreg-
ulation of p53 expression could also play a role. Rod-
rigues et al. reported that in HT29 cells mutated p53 is
highly expressed [67]. Similar to HT29 cells, Caco-2 cells
also contain a mutated p53 gene [68]. Overexpression of
p53 is found in colon tumors and is associated with low
chances on disease-free survival [69]. Recently, it was
described that EGR1 is required for p53 tumor suppres-
sion [70]. EGR1 was the gene most induced by curcumin
at the early time points. In HT29 cells treated with a mito-
sis-inhibiting peptide expression of EGR1 increased
already after 20 minutes [71]. Therefore, also in the case
of curcumin early upregulation of EGR1 could be related
to growth inhibition. Interestingly, endothelial cells con-
trasted with HT29 cells in that induced EGR1 expression
in these cells was found to be suppressed by curcumin
[72]. Another interesting observation in our study is the
differential expression of p16(INK4) (CDKN2A), RB1 and
p53 in response to curcumin. Functions of these genes,
working together in a signalling network regulating cell
cycle, are often impaired in cancer cells [73]. Other inter-
esting pathways that were influenced by curcumin are
MAPK signal transduction and DNA repair.
In the study by Mariadason et al. [74] gene expression
changes in SW620 cells in response to curcumin (25 µM)
were measured at time points between 30 minutes and 48
hours. Of the 6253 genes analysed by Mariadason et al.
[74], 1350 genes are present in our study. In this subset,
genes that were more than 1.5-fold up- or downregulated
were identified and compared with our data. Several genes
showed a similar response to curcumin in SW620 and
HT29 cells (i.e. up- or downregulation in both cell types),
for example activating transcription factor 4 (ATF4; up),
vascular endothelial growth factor (VEGF; up),
proteasome subunit PSMD8 (up), glutathione reductase
(GSR; up), adenosine kinase (ADK; up), RAN binding
protein 2-like 1 (RANBP2L1; down), prostaglandin D syn-
thase (PTGDS; up), signal sequence receptor alpha (SSR1;
down), ribonuclease 4 (RNASE4; down). Although both
studies used colon cancer cells, there were also differences
in response to curcumin between SW620 and HT29 cells.
However, the fact that cell lines differ in their response to
a food component is not surprising, since we found con-
siderable differences between twelve human colon cancer
cell lines when their RNA expression profiles under stand-
ard optimal culture conditions were compared (unpub-
lished results). Moreover, the fact that SW620 colon
cancer cells were derived from a metastasis of colon can-
cer, whereas HT29 cells were derived from a primaryJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/8
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colon tumor, implies that substantial physiological differ-
ences exist between these cell lines, which could contrib-
ute to the differences in gene expression profile in
response to curcumin. In our study expression of fewer
genes was changed in Caco-2 cells than in HT29 cells after
short-term exposure to curcumin. Consistent with this
observation, it was reported earlier that HT29 cells are
more sensitive to curcumin than Caco-2 cells [75].
Curcumin is an anti-inflammatory agent and can act as a
natural non-steroidal anti-inflammatory drug (NSAID).
Some of the genes differentially expressed in response to
curcumin in our study were also differentially expressed in
human colon cancer cells lines in response to other non-
steroidal compounds with anti-inflammatory action
(NSAIDs) such as aspirin or sulindac [76]. For example,
expression of ASNS, ATF4 and MTHFD2 was upregulated
by sulindac and expression of BUB1B and PDCD2 was
downregulated by aspirin. Similar changes in gene expres-
sion were found in our study in response to curcumin. In
a microarray study with rat colon carcinoma cells, it was
found that a large proportion of the genes differentially
expressed in response to aspirin were also differentially
expressed in the same direction in response to butyrate
[27]. In invasive human colonocytes butyrate inhibited
urokinase plasminogen activator (uPA) activity, and
downregulated PCNA and TP53 levels after exposure for
12–18 hours [77]. In our study a similar response was
found, as curcumin reduced expression of PCNA, TP53
and PLAU (uPA). This indicates that there may be some
overlap in response and in mechanism of action between
different NSAIDs like curcumin, aspirin and sulindac, but
also between NSAIDs and butyrate. However, both aspirin
and sulindac increased expression of several metal-
lothionein genes, which were downregulated by curcumin
in our study [76].
Two studies looked at the effect of curcumin and demeth-
oxycurcumin on gene expression in human umbilical vein
endothelial cells using microarrays [78,79]. In these cells
curcumin or demethoxycurcumin upregulated expression
of cyclin-dependent kinase inhibitor 2D (p19INK4D) and
downregulated expression of PCNA, HDAC2, MAP2K1
and PLAU. This is consistent with our results, where
curcumin exposure resulted in an increased expression of
cyclin-dependent kinase inhibitor 2A (CDKN2A) and a
decreased expression of PCNA, HDAC1, MAP2K2 and
PLAU. It is interesting to see that human cell lines derived
from different origin (colon and umbilical vein) show
similar responses to curcumin.
Conclusions
In conclusion, this study describes changes in gene expres-
sion profiles in colon cancer cells in response to exposure
to curcumin and relates these gene expression changes to
functional and physiological processes. To our knowl-
edge, this is the first study that uses a genomics approach
to investigate in detail the mechanisms of effects of
curcumin in colon cancer cells. Studying both early and
later time points allowed us to identify genes that changed
in expression with time of exposure. Some known effects
of curcumin were confirmed (G2/M cell cycle arrest,
induction of phase-II genes) and the existing knowledge
was extended with extra information (e.g. time points of
the observed changes and genes involved or linked to
these physiological effects). Also, potential new leads to
mechanisms explaining the biological activity of
curcumin were identified, for example the effect on tubu-
lin genes and differential expression of p16(INK4)/TP53/
RB1. Studying expression changes of thousands of genes
has provided increased insight into the mechanism of
action of curcumin in colon cancer cells, helping us to
understand how this compound can protect against devel-
opment of colon cancer.
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